Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 906-912

  Alousi, Amin M ^a   Brammer, Jonathan E ^a   Saliba, Rima M ^a   Andersson, Borje ^a   Popat, Uday ^a   Hosing, Chitra ^a   Jones, Roy ^a   Shpall, Elizabeth J ^a   Khouri, Issa ^a   Qazilbash, Muzaffar ^a   Nieto, Yago ^a   Shah, Nina ^a   Ahmed, Sairah ^a   Oran, Betul ^a   Al Atrash, Gheath ^a   Ciurea, Stefan ^a   Kebriaei, Partow ^a   Chen, Julianne ^a   Rondon, Gabriela ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute; Chronic; Graft versus host disease; Marrow; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION; SURVIVAL; UNRELATED DONORS; ADOLESCENT; ALLOGRAFT; ANALOGS AND DERIVATIVES; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84928124919     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.026     Document Type: Article

References (24)

1. Alousi A.M., Bolanos-Meade J., Lee S.J. Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant 2013, 19(1 Suppl):S102-S108.
2. Li Y., Li X.C., Zheng X.X., et al. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999, 5:1298-1302.
3. Fischer A.C., Ruvolo P.P., Burt R., et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. JImmunol 1995, 154:3713-3725.
4. Beschorner W.E., Hess A.D., Shinn C.A., Santos G.W. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation 1988, 45:209-215.
5. Jenkins M.K., Schwartz R.H., Pardoll D.M. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988, 24:1655-1658.
6. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
7. Kanakry C.G., Ganguly S., Zahurak M., et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013, 5:211ra157.
8. Luznik L., Fuchs E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010, 47:65-77.
9. Kanakry C.G., O'Donnell P.V., Furlong T., et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JClin Oncol 2014, 32:3497-3505.
10. Thall P.F., Simon R.M., Estey E.H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995, 14:357-379.
11. Thall P.F., Simon R.M., Estey E.H. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. JClin Oncol 1996, 14:296-303.
12. Popat U.R., Bassett R., Chen J., et al. Allogeneic transplantation for myelofibrosis: benefit of dose intensity. JClin Oncol 2013, 31. (suppl; abstr 7011).
13. Mohty M., Malard F., Blaise D., et al. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer 2015, 121:562-569.
14. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
17. Devine S.M., Owzar K., Blum W., et al. Aphase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502. ASH Annual Meeting Abstracts 2012 Blood 2012, 120:230.
18. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
19. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
20. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
21. Sorror M.L., Martin P.J., Storb R.F., et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 2014, 124:287-295.
22. Sorror M.L., Storb R.F., Sandmaier B.M., et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. JClin Oncol 2014, 32:3249-3256.
23. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
24. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1835-1844.